I can only elaborate on what I've experienced. Certainly, I've not seen transparency to date.
Our recommendation was to not use old data as the expert. However, during the time that we were trying to establish the evidence base, it seems that the working group was already working on evidence—although I don't know where it came from, since we had not completed our review. When we went to finalize things and there was all of the old data included in the evidence, we were told this was because the task force had demanded that this evidence be included.
I asked where the overdiagnosis number was coming from, because this is a key number. If you say, as we said earlier, that the overdiagnosis rate is 50%, what that means is that, if you're using an old trial with the benefit of 15% and you say that 50% of those don't matter, then you're down to 7%. If you take the newer trials at 40% benefit and you say there's zero overdiagnosis, then you have a 40% benefit. The evidence review panel did not know where that number came from. That is not a number that they were supplying to the task force working group.